首页> 外文OA文献 >It is reasonable to treat patients with type 1 hepatorenal syndrome with midodrine and octreotide

【2h】

It is reasonable to treat patients with type 1 hepatorenal syndrome with midodrine and octreotide

机译：用米多君和奥曲肽治疗1型肝肾综合征患者是合理的

页面导航

摘要
著录项
相似文献
相关主题

摘要

A critical appraisal and clinical application of Esrailian E, Pantangco ER, Kyulo NL, Hu KQ, Runyon BA. Octreotide/midodrine therapy significantly improves renal function and 30-day survival in patients with type 1 hepatorenal syndrome. Dig Dis Sci. 2007;52(3):742-748. doi: 10.1007/s10620-006-9312-0

机译：Esrailian E，Pantangco ER，Kyulo NL，Hu KQ，Runyon BA的重要评估和临床应用。奥曲肽/米多君疗法可显着改善1型肝肾综合征患者的肾功能和30天生存率。 Dig Dis Sci。 2007; 52（3）：742-748。 doi：10.1007 / s10620-006-9312-0

著录项

作者
Kane William;
展开▼
作者单位

展开▼
年度 2016
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Combination treatment with octreotide, midodrine, and albumin improves survival in patients with type 1 and type 2 hepatorenal syndrome. [J] . Skagen C, Einstein M, Lucey MR Journal of clinical gastroenterology . 2009 ,第7期

机译：奥曲肽，米多君和白蛋白的联合治疗可改善1型和2型肝肾综合征患者的生存率。
2. Octreotide/Midodrine Therapy Significantly Improves Renal Function and 30-Day Survival in Patients with Type 1 Hepatorenal Syndrome [J] . Eric Esrailian, Eugene R. Pantangco, Namgyal L. Kyulo, Digestive Diseases and Sciences . 2007 ,第3期

机译：奥曲肽/米多君治疗显着改善1型肝肾综合征患者的肾功能和30天生存率
3. Terlipressin is superior to midodrine/octreotide for hepatorenal syndrome type 1 [J] . Kalambokis Georgios N., Baltayiannis Gerasimos, Christodoulou Dimitrios, European journal of gastroenterology and hepatology . 2017 ,第12期

机译：Terlipressin优于中莨菪碱/八氧化钠，用于Hepatorenal综合征1型
4. Advances in the pathogenesis and treatment of type 1 and type 2 hepatorenal syndrome [C] . V. ARROYO, J. FERNANDE Falk Symposium . 2007

机译：1型和2型Hepatorenal综合征的发病机制和治疗的进展
5. Incidence of hypoglycemia and associated costs in Type 1and Type 2 diabetes patients treated with insulin analogs vs. human insulin: A retrospective cohort study. [D] . Shah, Hiren P. 2014

机译：使用胰岛素类似物与人胰岛素治疗的1型和2型糖尿病患者的低血糖发生率和相关费用：一项回顾性队列研究。
6. Norepinephrine is More Effective Than Midodrine/Octreotide in Patients With Hepatorenal Syndrome-Acute Kidney Injury: A Randomized Controlled Trial [O] . Eman Ibrahim El-Desoki Mahmoud, Doaa H Abdelaziz, Sherief Abd-Elsalam, 2021

机译：Norepinephrine比患有Hepatorenal综合征 - 急性肾损伤的患者中肌酐/ octreotide更有效：随机对照试验
7. Combination octreotide, midodrine, and albumin may improve survival in patients with Hepatorenal syndrome, but the evidence is weak [O] . Szafranski Jacob 2017

机译：联合奥曲肽，米多君和白蛋白可以改善肝肾综合征患者的生存率，但证据不足

It is reasonable to treat patients with type 1 hepatorenal syndrome with midodrine and octreotide

摘要

著录项

相似文献

相关主题

期刊订阅